Rising Prevalence of Chronic Diseases is Driving European Biologics Market

European biologics market is estimated to grow at a CAGR of 7.9% during the forecast period. Rising incidences of chronic diseases are reflecting positively on the European biologics market. A significant rise in the prevalence of cancer and autoimmune diseases is supporting to drive market growth. As per the European Commission, in EU-27 countries, the cancer burden is anticipated to have increased to 2.7 million new incidences (excluding non-melanoma skin cancer) in 2020. Biologics drugs act as an immune system substance that supports to augment the body’s ability to fight against cancer. Further, the increasing geriatric population is leading to an increasing prevalence of rheumatoid arthritis in the region. As per the Eurostat, in 2019, over one fifth (20.3%) of the EU-27 population was aged 65 and above. 

Browse the full report description of "European Biologics Market Size, Share & Trends Analysis Report, By Product (Antibody Therapeutics, Vaccines, Cell Therapy, Gene Therapy, and Others), By Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/european-biologics-market

This is encouraging the adoption of biologics in the region which may be prescribed for the treatment of autoimmune diseases, which include several kinds of arthritis, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Biologics are genetically engineered drugs that are intended to interact with the immune response to reduce the damaging effects of rheumatologic disorders. It works by disrupting the inflammation process that results in joint pain and destruction. For rheumatoid arthritis, these drugs particularly target proteins that are involved in joint inflammation. It can also be provided alone or along with traditional drugs to support slowing down the progression of rheumatoid arthritis. 

Scope of the European Biologics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Product and Application
• Countries Covered- UK, Germany, France, Spain, Italy, and Rest of Europe
• Competitive Landscape- AbbVie Inc., Amgen Inc., Eli Lilly and Co., F. Hoffman-La Roche AG, and Boehringer Ingelheim GmbH

Recent Strategic Initiatives in the European Biologics Market

• In March 2019, Roche declared the European Commission approval of MabThera (rituximab) to treat adults suffering from moderate to severe pemphigus vulgaris (PV). It is the first biologic therapy approved by the European Commission for PV and the first key innovation in the treatment of the condition in over 60 years. In June 2018, it was approved by the US FDA and after this approval, MabThera is now approved for the treatment of four autoimmune diseases in the US and Europe.
• In June 2018, Boehringer Ingelheim declared its plans to invest nearly $269.2 million into a new biological development center (BDC) at the company’s R&D site in Biberach, Germany. The center is a major building block that encourages the company’s long-term strategy to enhance the share of pipeline’s biologicals.

Key questions addressed by the report

• What is the market growth rate?
• Which segment/country dominates the market in the base year?
• Which segment/country will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID-19 forecast

o Most affected segment/country

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

European biologics Market-Segmentation

By Product

• Antibody Therapeutics
• Vaccines
• Cell Therapy
• Gene Therapy
• Others

By Application

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

European biologics Market– Segment by Country

• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/european-biologics-market